2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
-
- Liana Fraenkel
- Berkshire Medical Center, Pittsfield, Massachusetts, and Yale University School of Medicine New Haven Connecticut
-
- Joan M. Bathon
- Columbia University Irving Medical Center New York Presbyterian Hospital New York New York
-
- Bryant R. England
- University of Nebraska Medical Center and VA Nebraska‐Western Iowa Health Care System Omaha Nebraska
-
- E. William St.Clair
- Duke University Medical Center Durham North Carolina
-
- Thurayya Arayssi
- Weill Cornell Medicine–Qatar Doha Qatar
-
- Kristine Carandang
- University of California San Diego
-
- Kevin D. Deane
- University of Colorado Aurora
-
- Mark Genovese
- Stanford University Medical Center Palo Alto California
-
- Kent Kwas Huston
- The Center for Rheumatic Disease/Allergy and Immunology Kansas City Missouri
-
- Gail Kerr
- Veterans Affairs Medical Center Georgetown and Howard University Washington DC
-
- Joel Kremer
- Albany Medical College and The Center for Rheumatology Albany New York
-
- Mary C. Nakamura
- University of California San Francisco
-
- Linda A. Russell
- Hospital for Special Surgery New York New York
-
- Jasvinder A. Singh
- University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center Birmingham Alabama
-
- Benjamin J. Smith
- Florida State University College of Medicine School of Physician Assistant Practice Tallahassee
-
- Jeffrey A. Sparks
- Brigham and Women’s Hospital and Harvard Medical School Boston Massachusetts
-
- Shilpa Venkatachalam
- Global Healthy Living Foundation Upper Nyack New York
-
- Michael E. Weinblatt
- Brigham and Women’s Hospital and Harvard Medical School Boston Massachusetts
-
- Mounir Al‐Gibbawi
- American University of Beirut Beirut Lebanon
-
- Joshua F. Baker
- Corporal Michael J. Crescenz VA Medical Center and the University of Pennsylvania Philadelphia Pennsylvania
-
- Kamil E. Barbour
- Centers for Disease Control and Prevention Atlanta Georgia
-
- Jennifer L. Barton
- Oregon Health & Science University and VA Portland Health Care System Portland Oregon
-
- Laura Cappelli
- Johns Hopkins Medicine Baltimore Maryland
-
- Fatimah Chamseddine
- American University of Beirut Beirut Lebanon
-
- Michael George
- University of Pennsylvania Philadelphia
-
- Sindhu R. Johnson
- Toronto Western Hospital Mount Sinai Hospital Institute of Health Policy Management and Evaluation University of Toronto Toronto Ontario Canada
-
- Lara Kahale
- American University of Beirut Beirut Lebanon
-
- Basil S. Karam
- American University of Beirut Beirut Lebanon
-
- Assem M. Khamis
- American University of Beirut Beirut Lebanon
-
- Iris Navarro-Millán
- Weill Cornell Medicine New York New York
-
- Reza Mirza
- University of Toronto Toronto Ontario Canada
-
- Pascale Schwab
- Oregon Health & Science University and VA Portland Health Care System Portland Oregon
-
- Namrata Singh
- University of Washington Seattle
-
- Marat Turgunbaev
- American College of Rheumatology Atlanta Georgia
-
- Amy S. Turner
- American College of Rheumatology Atlanta Georgia
-
- Sally Yaacoub
- American University of Beirut Beirut Lebanon
-
- Elie A. Akl
- American University of Beirut Beirut Lebanon
抄録
<jats:sec><jats:title>Objective</jats:title><jats:p>To develop updated guidelines for the pharmacologic management of rheumatoid arthritis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The guideline addresses treatment with disease‐modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high‐risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This clinical practice guideline is intended to serve as a tool to support clinician and patient decision‐making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision‐making process based on patients’ values, goals, preferences, and comorbidities.</jats:p></jats:sec>
収録刊行物
-
- Arthritis Care & Research
-
Arthritis Care & Research 73 (7), 924-939, 2021-06-08
Wiley